All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2026-01-15.
From the record
STAAR Surgical Company's filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2026-01-15) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+12.6% a year over 10 filed years; profitable in 6 of 10.
From the record
STAAR Surgical Company's 10 filed years say what it did: revenue went from $82 million in fiscal 2016 to $239 million in fiscal 2026, up 12.6% a year; it rose in 7 of 9 years; the deepest fall was 26% from fiscal 2023 to fiscal 2026; net income was positive in 6 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: STAAR Surgical Company's shareholder treatment is put at 6.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 31% of 8 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -23%: lost 23¢ per shareholder dollar. Leverage 24%: owes 24¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-01-02, STAAR Surgical Company lost about 23 cents for every dollar of shareholders' money, and gross profitability: its products earned about 40 cents per dollar of everything the company owns. Leverage: it owed about 24 cents per dollar of assets, and net share issuance: its share count grew 0.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 19% of 8 in its family; net margin -33.6%.
From the record
STAAR Surgical Company's standing among 8 graded names in its industry family: revenue of $239 million in fiscal 2026 ranks in the bottom 31% by size; a net margin of -33.6% ranks in the bottom 19%; revenue growth of 0% a year over the last 3 filed years ranks in the bottom 6% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 19% of 6 in its family for leadership; chief executive since 2026.
From the record
STAAR Surgical Company's leadership, from its insiders' filings and its current reports: the chief executive on the record is Foust, Warren (President and CEO, as filed), filing under that title since 2026-02-04, 9 months (bottom 25% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 2.9 years (bottom 25%); 16 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 7%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 45% of 8 in its family for room to expand.
From the record
STAAR Surgical Company's room to grow, from the newest filed statements (fiscal 2026): cash of $153 million against no long-term debt tagged leaves 33.9% of its assets as net cash, top 31% of its family; cash from operations less capital spending is -16.7% of revenue (bottom 19%); a gross margin of 76.2% (top 25%); research spending of 16.7% of revenue (top 42%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 10% of 8 in its family for growth drivers.
From the record
STAAR Surgical Company's growth drivers, from the filed years to fiscal 2026: revenue grew 0% a year over the last three filed years against 12.6% over all 10, slowing (bottom 19% of its family); the newest year grew -23.4% (bottom 6%); research spending grew 3.6% a year (bottom 8%); capital spending grew -31.4% a year (bottom 6%) (its annual reports). STAAR Surgical Company tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 10% of 8 in its family for expectations against reality.
From the record
STAAR Surgical Company's newest year against its own record: revenue of $239 million in fiscal 2026 came in 33.4% below the $360 million its prior three years' pace pointed to (bottom 19% of its family); net income of $80 million against a prior three-year average of $14 million (bottom 6%); a net margin of -33.6% against 5.6% before (bottom 6%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made